Letermovir

Overview

Letermovir is a novel anti-CMV compound which targets the pUL56 (amino acid 230-370) subunit of the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors. It has a novel mode of action targets the enzyme UL56 terminase and keep active to other drug-resistant virus. It has been approved in prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Source summary: Letermovir research chemical for antiviral studies; small-molecule inhibitor for lab use in biochemical assays and mechanistic research.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Infection | CMV

Product Information

• Catalog No.: B2693-460490
• CAS No.: 917389-32-3
• Molecular Formula: C29H28F4N4O4
• Molecular Weight: 572.56
• Purity: ≥98%
• Storage: Powder : -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
• Solubility: In Vivo : 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90%(20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution

Source

Original product source